SCHEMBL2675306

SCHEMBL2675306

O=c1[nH]c(-c2ccc(S(=O)(=O)N3CCc4cc(-c5ccc(C(F)(F)F)cc5)ccc43)cc2Cl)no1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 7/20 0.47
MAPT P10636 5/20 0.42
CYP11B2 P19099 5/20 0.42
CNR1 P21554 1/20 0.41
TYK2 P29597 3/20 0.40
NR1I2 O75469 1/20 0.39
BRS3 P32247 1/20 0.39
RORC P51449 1/20 0.39
NR1H3 Q13133 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
JAK2 O60674 3/20 0.37
LMNA P02545 1/20 0.37
JAK1 P23458 1/20 0.37
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1396635 0.90 CYP11B1 (0.41) CYP11B1MAPTCYP11B2CNR1TYK2
SCHEMBL1396286 0.90 CYP11B1 (0.44) CYP11B1CYP11B2CNR1TYK2NR1I2
SCHEMBL2675371 0.89 CYP11B1 (0.55) CYP11B1MAPTCYP11B2CNR1TYK2
SCHEMBL2347408 0.88 CYP11B1 (0.42) CYP11B1CYP11B2CNR1TYK2NR1I2
SCHEMBL2674505 0.85 CYP11B1 (0.44) CYP11B1MAPTCYP11B2CNR1TYK2
SCHEMBL1396289 0.84 CYP11B1 (0.50) CYP11B1MAPTCYP11B2CNR1TYK2
SCHEMBL1396621 0.83 CYP11B1 (0.41) CYP11B1MAPTCYP11B2CNR1NR1I2
SCHEMBL2675765 0.83 CYP11B1 (0.45) CYP11B1MAPTCYP11B2CNR1TYK2
SCHEMBL1396614 0.82 CNR1 (0.39) CYP11B1CNR1NR1I2BRS3RORC
SCHEMBL1396664 0.81 BRS3 (0.39) CYP11B1CNR1NR1I2BRS3RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173674-B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-08 US claimed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US claimed
EP-2102198-B1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2015-02-25 EP disclosed
US-8173674-B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-08 US disclosed
US-8173674-B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-08 US disclosed
US-8173674-B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-08 US disclosed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US disclosed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US disclosed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US disclosed
EP-2102198-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-09-23 EP disclosed
WO-2008071311-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-06-19 WO disclosed
EP-1932843-A1 Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals sanofi-aventis (FR) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS PPARD, PPARG, PPARA CYP11B1 89/4885MAPT 2366/4885CYP11B2 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.